ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,621 to 1,640 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One All-cause MA-RTI From Day 1 to Day 181 Post-delivery317 of 3,557

144 of 1,771

0.8 points

-0.9 to 2.3

5,328NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One SAE From Day 1 to Day 181 Post-delivery827 of 3,557

395 of 1,771

0.9 points

-1.5 to 3.3

5,328NCT04605159

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding145 of 2,662

91 of 2,650

2.0 points

0.9 to 3.1

5,312NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of Thrombolysis in Myocardial Infarction (TIMI) Major4 of 2,662

9 of 2,650

-0.2 points

-0.5 to 0.1

5,312NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of GUSTO Severe / Life-threatening9 of 2,662

6 of 2,650

0.1 points

-0.2 to 0.4

5,312NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of ACUITY Major Bleeding Without Hematoma >/= 5 cm43 of 2,662

29 of 2,650

0.5 points

-0.1 to 1.2

5,312NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: serious adverse events48 of 2,662

55 of 2,650

-0.3 points

-1.0 to 0.5

5,312NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of Procedure Events [Abrupt Closure, Threatened Abrupt Closure, Need for Urgent Coronary Artery Bypass Graft (CABG) Surgery, Unsuccessful Procedure, New Thrombus or Suspected Thrombus, and/or Acute Stent Thrombosis]122 of 2,656

142 of 2,645

-0.8 points

-2.0 to 0.4

5,301NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of Stent Thrombosis5 of 2,654

16 of 2,641

-0.4 points

-0.8 to -0.1

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality or MI180 of 2,654

204 of 2,641

-0.9 points

-2.3 to 0.5

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of MI177 of 2,654

191 of 2,641

-0.6 points

-1.9 to 0.8

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of Stroke7 of 2,654

5 of 2,641

0.1 points

-0.2 to 0.4

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality6 of 2,654

18 of 2,641

-0.5 points

-0.9 to -0.1

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)185 of 2,654

210 of 2,641

-1.0 points

-2.4 to 0.4

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of IDR19 of 2,654

24 of 2,641

-0.2 points

-0.7 to 0.3

5,295NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause364 of 618

3,780 of 4,661

-22.2 points

-26.3 to -18.2

5,279NCT05834348

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality or MI213 of 2,647

233 of 2,629

-0.8 points

-2.3 to 0.7

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of MI189 of 2,647

201 of 2,629

-0.5 points

-1.9 to 0.9

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of All-cause Mortality35 of 2,647

45 of 2,629

-0.4 points

-1.1 to 0.3

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Cangrelor vs Clopidogrel: Incidence of Stroke6 of 2,647

5 of 2,629

0.0 points

-0.2 to 0.3

5,276NCT00385138

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=82

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04605159-e50c2f3a",
        "title": "RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One All-cause MA-RTI From Day 1 to Day 181 Post-delivery",
        "summary": "317 of 3557 against 144 of 1771; risk difference 0.8 points, 95% interval -0.9 to 2.3; NCT04605159, A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",
        "record": "/library/comparisons/NCT04605159-e50c2f3a",
        "nct_id": "NCT04605159",
        "kind": "outcome",
        "participants": 5328,
        "risk_difference": {
          "value": 0.007810050628253559,
          "lower": -0.00850209872708036,
          "upper": 0.02318826622202931
        },
        "group_1": "317 of 3,557",
        "group_2": "144 of 1,771",
        "difference": "0.8 points",
        "interval": "-0.9 to 2.3",
        "trial_title": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers"
      },
      {
        "id": "NCT04605159-ff2e7bca",
        "title": "RSV MAT Group - Mother vs Placebo Group - Mother: Number of Maternal Participants With at Least One SAE From Day 1 to Day 181 Post-delivery",
        "summary": "827 of 3557 against 395 of 1771; risk difference 0.9 points, 95% interval -1.5 to 3.3; NCT04605159, A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",
        "record": "/library/comparisons/NCT04605159-ff2e7bca",
        "nct_id": "NCT04605159",
        "kind": "outcome",
        "participants": 5328,
        "risk_difference": {
          "value": 0.009461465427044624,
          "lower": -0.014698086716277366,
          "upper": 0.032982582247099906
        },
        "group_1": "827 of 3,557",
        "group_2": "395 of 1,771",
        "difference": "0.9 points",
        "interval": "-1.5 to 3.3",
        "trial_title": "A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=83",
  "request_id": "2FlfNZ7Zubm9Pkcw"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?